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Background: Mendelian randomization (MR) has been widely applied to causal
inference in medical research. It uses genetic variants as instrumental variables
(IVs) to investigate putative causal relationship between an exposure and an
outcome. Traditional MR methods have dominantly focussed on a two-sample
setting in which IV-exposure association study and IV-outcome association study
are independent. However, it is not uncommon that participants from the two
studies fully overlap (one-sample) or partly overlap (overlapping-sample).
Methods: We proposed a method that is applicable to all the three sample
settings. In essence, we converted a two- or overlapping- sample problem to a
one-sample problem where data of some or all of the individuals were incomplete.
Assume that all individuals were drawn from the same population and
unmeasured data were missing at random. Then the unobserved data were
treated au pair with the model parameters as unknown quantities, and thus,
could be imputed iteratively conditioning on the observed data and estimated
parameters using Markov chain Monte Carlo. We generalised our model to allow
for pleiotropy and multiple exposures and assessed its performance by a number
of simulations using four metrics: mean, standard deviation, coverage and power.
Results: Higher sample overlapping rate and stronger instruments led to
estimates with higher precision and power. Pleiotropy had a notably negative
impact on the estimates. Nevertheless, overall the coverages were high and our
model performed well in all the sample settings.
Conclusions: Our model offers the flexibility of being applicable to any of the
sample settings, which is an important addition to the MR literature which has
restricted to one- or two- sample scenarios. Given the nature of Bayesian
inference, it can be easily extended to more complex MR analysis in medical
research.
Keywords: Mendelian randomization; Bayesian approach; missing data;
overlapping-sample; multiple exposures
Background
Many questions in medical research address putative causal nature of the relation-
ship between a clinical outcome and a corresponding risk factor or exposure. Ran-
domised controlled trials (RCTs) are ideal for this purpose, but are often infeasible
due to cost or ethical considerations. With the aid of proper statistical methodology,
causal inference can be made from observational studies. This is a context where
Mendelian randomization (MR) [1, 2, 3] can be extremely useful. MR uses genetic
variants as instrumental variables (IVs) to estimate the causal effect of an expo-
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sure on an outcome of interest [4, 5]. Without loss of generality, we shall hereafter
assume the IVs are single nucleotide polymorphisms (SNPs).
MR analysis requires data from two association studies: IV-exposure and IV-
outcome. Most of MR methods [6, 7, 8, 9] have focussed on a two-sample scenario
where the IV-exposure and IV-outcome associations were estimated separately from
independent studies. In other words, there were no shared individuals between the
two studies. A limited number of one-sample MR, if a single group of individuals
come with a complete set of measurements (IVs, exposure and outcome), methods
are available in the literature [10, 11, 12, 5]. Little attention has, however, been
devoted to overlapping samples where the two studies have a subset of individuals
in common. For example, an investigator has identified a number of SNPs associated
with diabetes from a genome-wide association study (GWAS). She is interested in
whether gene expression levels play a causal role in the risk of diabetes. But gene
expression can be measured only from a subset of individuals in the diabetes GWAS
due to cost. Another example is that the investigator has collected data from two
small groups of individuals to estimate the IV-BMI and IV-diabetes associations.
She aims to use MR to estimate the causal effect of BMI on diabetes. A previous
study has a complete set of observed data on IV, BMI and diabetes. A natural way
of enhancing statistical power of her analysis is to incorporate the previous study
into her current studies. To the best of our knowledge, only Burgess et al [13] has
investigated biases for overlapping samples.
Here we propose a Bayesian approach that is applicable to one-, two- and
overlapping- sample settings. Moreover we generalise the approach by allowing for
an IV to be associated with multiple exposures.
Methods
Model
Let U denote a set of unobserved confounders which could possibly distort the causal
relationship between the exposure X and the outcome Y . Let Z be an instrumental
SNP (the multiple SNP situation is considered later) which satisfies the following
three assumptions ([10]):
A1: Z is associated with X;
A2: Z is independent of U ;
A3: Z is independent of Y , conditioning on (X,U).
These assumptions are graphically expressed in Figure 1. The Z → X arrow repre-
sents a non-zero association between the IV and the exposure, in accord with A1.
A2 follows from the graph because there is no arrow between Z and U . A3 is also
satisfied (it would not if an arrow pointed directly from Z to Y ). The X → Y arrow
represents the putative causal effect of X on Y , which is the interest of our study.
Consider a study with multiple exposures and each instrumental SNP associated
with at least one exposure. Without loss of generality, we shall hereafter restrict
attention to the case where we have three exposures, X = (X1, X2, X3), and three
IVs, Z = (Z1, Z2, Z3). Figure 2 depicts our model and parameter notations, with
β1, β2 and β3 representing the causal effects of the exposures X1, X2 and X3 on the
outcome Y , respectively; δ1, δ2, δ3 and δ4 representing the effects of the confounder
U on the three exposures and Y , respectively. For simplicity, we assume that there
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are no direct associations among the exposures and that the IVs are mutually
independent. The Z1 → X1 association is quantified as α1 and the Z2 → X2
association as α2. Both Z2 and Z3 are associated with X3 through parameters α3
and α4. Z1 and Z3 are “valid instruments” as they satisfy all the above stated
MR assumptions. However, Z2 violates assumption A3 for the causal relationship
between X2 and Y because the effect of Z2 on Y is mediated by both X2 and X3 -
a problem of horizontal pleiotropy [14].
By assuming linearity and additivity of the conditional dependencies, we build
our model as follows.
U ∼ N(0, 0.1) (1)
X1|Z1, U ∼ N(ω1 + α1Z1 + δ1U, σ21), (2)
X2|Z2, U ∼ N(ω2 + α2Z2 + δ2U, σ22), (3)
X3|Z2, Z3, U ∼ N(ω3 + α3Z2 + α4Z3 + δ3U, σ23), (4)
Y |X1, X2, X3, U ∼ N(ωY + β1X1 + β2X2 + β3X3 + δ4U, σ2Y ), (5)
where N(a, b) stands for a normal distribution with mean a and variance b. The ω
parameters are unknown intercepts and the σs are standard deviations of indepen-
dent random noise terms. The parameters of primary inferential interest are the βs,
each representing the causal effect of a particular exposure on the outcome. The α
parameters quantify the strengths of pairwise associations between the instruments
and the exposures. They are often referred to as “instrument strengths”, and should
be significantly different from zero to avoid “weak instrument bias” [15]. Finally,
the symbol U denotes a sufficient scalar summary of the unobserved confounders,
which we set to be drawn from a N(0, 0.1) distribution with its parameters not
identifiable from the likelihood. This model is built on the basis of the Bayesian
approach developed by Berzuini et al [5], with an extension to multiple exposures
and allowing for an IV to be associated with more than one exposure.
Our method
We propose a MR method that can be applied to all the aforementioned sample
settings (whether one-sample, two-sample or overlapping-sample). In essence, our
method converts a two- or overlapping- sample problem into a one-sample prob-
lem where the data of some (or all) of the individuals are incomplete, in the sense
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that these individuals have Z and X (but not Y ) measured or Z and Y (but not
X) measured. The method itself is very flexible in allowing for more general pat-
terns of missingness, but for simplicity we prefer to exclude such complications
from the ensuing discussion. We assume that all individuals are drawn from the
same population and unmeasured data are missing at random. Then whatever are
the unobserved variables (whether exposures or outcome), they are treated au pair
with the model parameters as unknown quantities, and thus, can be imputed itera-
tively from their distributions conditioning on the observed variables and estimated
parameters using Markov chain Monte Carlo - the best Bayesian tradition.
We start with introducing three distinct datasets as follows (with reference to
Figure 3 (a)):
• Dataset A: all individuals with observed values of Z, X and Y ;
• Dataset B: all individuals with observed values of Z and X only;
• Dataset C: all individuals with observed values of Z and Y only.
No individuals are common in A, B and C but they are drawn independently from
the same population. As discussed earlier, A may be collected from a previous study;
B and C may represent data from two independent IV-exposure and IV-outcome
association studies. If we combine A with B
D1 = A ∪B
and combine A with C
D2 = A ∪ C,
the three independent datasets will be converted to two non-independent datasets
D1 and D2 due to shared A - a typical overlapping-sample problem. If there is no
such data A, then B and C will form a two-sample problem.
As our approach is based on a model originally proposed for the one-sample sce-
nario, it requires a complete set of values of (Z, X, Y ). However, the outcome data
Y are missing in B and the exposure data X are missing in C. Within a Bayesian
approach, missing data are dealt with in a natural way, as all other unknown quan-
tities in the model. That is, we impute the missing values of Y in B by sampling
from its full conditional distribution, given the observed exposures and estimated
parameters β1, β2 and β3. Likewise, the missing values of X in C will be imputed
from their respective conditional distributions given the observed values of the in-
struments Z and the estimated values of parameters α1, α2, α3 and α4. Let Y
∗ be
imputed values of Y and X∗ = (X∗1 , X
∗
2 , X
∗
3 ) be imputed values of X. Given all the
datasets A,B and C, we proceed with the following Markov chain sampling scheme.
1. Set initial values for all the unknown parameters in the model. We also fix
the desired number of Markov iterations, with iteration index t.
2. At the tth iteration, with reference to Figure 3 (b), we replace the missing
values of Y in B with
Y ∗ = ω(t)Y + β
(t)
1 X1 + β
(t)
2 X2 + β
(t)
3 X3,
where (X1, X2, X3) are observed values in dataset B. Similarly, we replace
the missing values of X in C with
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X∗1 = ω
(t)
1 + α
(t)
1 Z1,
X∗2 = ω
(t)
2 + α
(t)
2 Z2,
X∗3 = ω
(t)
3 + α
(t)
3 Z2 + α
(t)
4 Z3,
where (Z1, Z2, Z3) are observed values in dataset C. The parameters with
superscript (t) are their estimated values at the tth iteration. When t = 0 they
are initial values of the parameters. Because all imputed data are calculated
as the expected values, both U and the random errors have vanished in this
step because they have zero mean.
3. Merge all the data, imputed and observed, into a new complete dataset (Figure
3 (c)).
4. Estimate model parameters based on the complete dataset obtained in Step
3 using Markov chain Monte Carlo (MCMC) methods and set t← t+ 1.
5. Repeat Steps 2-4 until t equals the specified number of iterations in Step 1.
The Priors
Here we discuss the choice of prior distributions of the unknown parameters involved
in Models (1)-(5). Let the priors for β = (β1, β2, β3) be independently normally
distributed with mean 0 and standard deviation 10 β1β2
β3
 ∼ N

 00
0
 ,
 10 0 00 10 0
0 0 10

 ,
and the IV strength parameters α = (α1, α2, α3, α4) be independently normally
distributed with mean 1 and standard deviation 0.3
α1
α2
α3
α4
 ∼ N


1
1
1
1
 ,

0.3 0 0 0
0 0.3 0 0
0 0 0.3 0
0 0 0 0.3

 .
U has been assumed to follow a normal distribution U ∼ N(0, 0.1) in Model (1).
The priors of the standard deviation parameters σ1, σ2, σ3 and σY are assumed to
follow a same inverse-gamma distribution σ(·) ∼ Inv-Gamma(3, 2).
Simulations
In our simulations, according to Models (1)-(5), we consider a total of 72 configu-
rations including
• 6 sample overlapping rates (100%, 80%, 60%, 40%, 20%, 0%)
• 2 IV strengths: α = (α1, α2, α3, α4) = 0.5 and 0.1
• 3 levels of the confounding effects of U on X: (δ1, δ2, δ3) = 1,0.5 and 0.1
• 2 levels of causal effects of X on Y : β = (β1, β2, β3) = 0.3 and 0.
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The effect of U on Y is set to 1 (δ4 = 1). In each configuration, we simulated 200
datasets, step by step, as follows.
1. Generate a dataset H which contains observed IVs (Z), exposures (X) and
outcome (Y ) from 1000 independent individuals.
2. Randomly sample nA individuals without replacement from H and take their
observations of (Z,X, Y ) as dataset A;
3. Randomly Sample nB individuals without replacement from H − A = {x ∈
H, x /∈ A} and take their observations of (Z,X) as dataset B;
4. Randomly sample nC individuals without replacement from H − A − B =
{x ∈ H, x /∈ A ∪B} and take their observations of (Z, Y ) as dataset C.
The sample size of B was set to be the same as that of C (i.e., nB = nC)
and the sample size of both D1 = A ∪ B and D2 = A ∪ C to 400. We define
overlapping rate as the percentage of the number of individuals from A (nA) in D1
(or equivalently, in D2). For example, if overlapping rate was 80%, then nA = 320
and nB = nC = 80. Similarly, for an overlapping rate of 60%, nA = 240 and
nB = nC = 160. When overlapping rate was 100%, we only used dataset A of sample
size 400 (or equivalently, D1 = D2 = A where nA = 400). For an overlapping rate
of 0%, we only used datasets B and C (i.e., D1 = B with nB = 400 and D2 = C
with nC = 400). Imputations of missing data and causal effect estimations were
then performed simultaneously using the MCMC methods ([16]) in Stan ([17, 18]).
Results
The performance of our method was assessed using 4 metrics: mean (posterior
mean), standard deviation, coverage (the proportion of the times that the 95%
credible interval contained the true value of the causal effect β) and power (the
proportion of the times that the 95% credible interval did not contain value zero
when β was non-zero), in terms of the estimated causal effects of X1, X2 and X3 on
the outcome Y (denoted as βˆ = (βˆ1, βˆ2, βˆ3)), both on the basis of data simulated
under the alternative hypothesis that the three causal effects are equal to 0.3, and
on the basis of data simulated under the null hypothesis that the three causal effects
are equal to 0. Note that the last metric was only applicable when β 6= 0 and a
high value of power indicates high sensitivity of the model to deviations of the data
from the null or, equivalently, a low expected probability of false negatives.
Table 1 shows a summary of results obtained under the alternative hypothesis.
Each row of the table corresponds to a configuration, defined by a particular value
for the overlapping rate, a particular value for the instrument strengths α and a
particular value of the δ parameters, this latter being interpreted to represent degree
of confounding.
When β = 0.3, if sample overlapping rate was high (80% or over), both the cover-
age and the power of the βˆs were consistently high (≥ 0.93). When the overlapping
rate was 60% or under, strong IVs (α = 0.5) resulted in high statistical power
(=1) while the impact of reduced IV strength (α = 0.1) became detrimental, even
more so when sample overlapping rate was reduced. When IVs were relatively weak
(α = 0.1), statistical power increased as confounding effects (δ) decreased. Overall,
where there was pleiotropy (in estimating β2 because there were two competing
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paths from Z2 to Y via X2 and X3) the results were notably worse than those with-
out pleiotropy (in estimating β1 and β3). As α increased, the averages of βˆs (mean)
became closer to the true value 0.3 and the variations (sd) decreased, concluding
that higher IV strength reduced bias and resulted in more precise estimates. As
an illustration of the reliability of our method, we note in Table 1 that despite the
greater posterior uncertainty for β2 across all the configurations (as indicated in the
sd column of the table), the posterior mean for this parameter remained relatively
close to the true value 0.3. Our model is ”honest about uncertainty”.
When β = 0 (Table 2), the coverages of the three estimated causal effects βˆs
were high (> 0.9) in all the configurations, indicating that the method does not
produce too many false positives - a quite important property in the context of
use of Mendelian Randomization. This implies that none of the sample overlapping
rate, IV strength and confounding effect has had much negative influence on the
results, although there seemed to be an increasing trend in bias and variation when
IV strength decreased. Coverages were high across Tables 1 and 2 regardless the
magnitude of the true causal effects.
Figures 4 and 5 depict, respectively, distributions of βˆs for each of the IV-strength
and overlapping rate configurations when the confounding effects δ = 1, for β = 0.3
and β = 0. Each point in a box plot represents the estimated causal effect β based
on one of the 200 simulated datasets. Higher overlapping rate led to a gain in
precision, which can be observed across the two figures, in which the blue boxes
became narrower in height as the sample overlapping rate increased and reached
minimum in the one-sample scenario (overlapping rate = 100%).
Discussion and Conclusions
In this paper we have proposed a Bayesian method that can effectively convert a
two-sample or overlapping-sample MR to a one-sample MR. It is noteworthy that
our method has the best performance in one-sample setting, which is unsurprising
because 1) our method has been developed on the basis of a Bayesian approach
tailored for one-sample MR [5]; 2) the percentage of imputed data becomes lower as
overlapping rate increases, and naturally, the uncertainty in data decreases. As dis-
cussed, our method provides the flexibility of combining data from previous studies
with current ones to enhance statistical power, which is particularly advantageous
as MR studies are often underpowered partly due to limited sample sizes.
It is also observed from our simulation results that pleiotropy (effect of Z2 on
Y mediated by both X2 and X3) resulted in the worst estimated causal effect,
because it involves two completing paths, and consequently, higher uncertainty in
estimation. This is, however, not a problem in our method only. Rather, it is an
issue commonly seen in MR studies [19, 20].
One limitation of our method is that we have focussed on a simple model with
only three IVs and three exposures and a moderate number of configurations. In the
real world, we often encounter much more complex data in which there are possibly
many (weak and/or correlated) IVs and (correlated) exposures and outcomes, which
tiggers a research topic of variable selections in future MR methodology [21].
Taken together, our method, developed from a Bayesian one-sample MR, can be
applied to any of the sample settings by means of treating missing data as unknown
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parameters which can then be imputed using MCMC. This is an important addition
to the existing MR literature where some methods can only be used for one-sample
and others for two-sample settings. Because of the nature of Bayesian inference,
our model can be easily extended to tackle more complex MR analysis in medical
research.
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Figure 1 Schematic representation of the three assumptions required in Mendelian
randomization. 1) Instrumental variable Z is associated with the exposure X; 2) Z is independent
of the confounder U ; 3) Z is independent of the outcome Y , conditioning on X and U .
[scale=0.5]assumptions.pdf
Figure 2 Diagram of our model and parameter settings. There are three instrumental variables
(Z1, Z2, Z3) and three exposures (X1, X2, X3). Z1 is associated with X1 only. Z3 is associated
with X3 only. Z2 is associated with both X2 and X3. For simplicity, we assume there is no direct
associations among the exposures and the instrumental variables are mutually independent.
[scale=0.45]fullmodel.pdf
Figure 3 Flowchart of imputations and merge of datasets A,B and C into a single complete
dataset. Solid rectangles in Steps (a) and (b) denote observed data. Dashed rectangles with Y ∗(t)
and X∗(t) in Step (b) represent imputed values of Y and X respectively in the specific tth
iteration. By merging all the observed and imputed data in A,B,C, we obtain a single complete
dataset in Step (c).
[scale=0.45]flowchart.pdf
Figure 4 Box plots of causal effects estimated from simulated data when
β = (β1, β2, β3) = 0.3 and δ = (δ1, δ2, δ3, δ4) = 1. Results with two instrument strengths
(top panels: α = (α1, α2, α3) = 0.5 and bottom panels: α = 0.1) are displayed, from left to
right, for estimated causal effect of X1, X2 and X3 on Y , denoted as βˆ1, βˆ2 and βˆ3 respectively.
Each panel consists results of six different sample overlapping rates ranging from 0 (leftmost) to 1
(rightmost) and each box plot represents causal effect estimated from 200 simulated datasets.
[width=17.3cm,height=9cm]simresultsAlternative.pdf
Figure 5 Box plots of causal effects estimated from simulated data when
β = (β1, β2, β3) = 0 and δ = (δ1, δ2, δ3, δ4) = 1. Results with two instrument strengths
(top panels: α = (α1, α2, α3) = 0.5 and bottom panels: α = 0.1) are displayed, from left to
right, for estimated causal effect of X1, X2 and X3 on Y , denoted as βˆ1, βˆ2 and βˆ3 respectively.
Each panel consists results of six different sample overlapping rates ranging from 0 (leftmost) to 1
(rightmost) and each box plot represents causal effect estimated from 200 simulated datasets.
[width=17.3cm,height=9cm]simresultsNull.pdf
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Table 1 Causal effects estimated from simulated data when β = (β1, β2, β3) = 0.3. Mean, standard
deviation (sd), coverage and power are displayed for the estimated causal effects of the exposures X1,
X2 and X3 on the outcome Y , denoted as βˆ1, βˆ2 and βˆ3 respectively. There are 36 configurations
containing six sample overlapping rates (100%, 80%, 60%, 40%, 20%, 0%), two levels of IV strengths
(α = (α1, α2, α3) = 0.5 and 0.1) and three levels of effects of the confounder U on the exposures
(δ = (δ1, δ2, δ3) = 1,0.5 and 0.1). The effect of U on Y (δ4) is set to 1.
overlapping rate α δ
βˆ1 βˆ2 βˆ3
mean sd coverage power mean sd coverage power mean sd coverage power
100% 0.5 1 0.300 0.001 0.955 1 0.300 0.002 0.965 1 0.300 0.001 0.990 1
0.5 0.301 0.006 0.960 1 0.301 0.004 0.985 1 0.300 0.002 0.985 1
0.1 0.301 0.006 0.960 1 0.301 0.009 0.975 1 0.300 0.006 0.950 1
0.1 1 0.302 0.006 0.965 1 0.303 0.010 0.970 1 0.300 0.006 0.975 1
0.5 0.306 0.009 0.950 1 0.309 0.015 0.975 1 0.301 0.009 0.985 1
0.1 0.319 0.029 0.945 1 0.324 0.050 0.940 1 0.300 0.029 0.980 1
80% 0.5 1 0.304 0.020 0.930 1 0.304 0.022 0.945 1 0.300 0.013 0.965 1
0.5 0.302 0.010 0.955 1 0.302 0.015 0.955 1 0.299 0.011 0.960 1
0.1 0.302 0.011 0.945 1 0.300 0.016 0.965 1 0.301 0.011 0.960 1
0.1 1 0.306 0.048 0.975 1 0.307 0.072 0.980 0.975 0.302 0.060 0.970 1
0.5 0.320 0.041 0.980 1 0.320 0.060 0.975 1 0.303 0.047 1.000 1
0.1 0.320 0.050 0.970 1 0.320 0.075 0.970 1 0.301 0.052 0.975 1
60% 0.5 1 0.302 0.020 0.950 1 0.299 0.027 0.945 1 0.302 0.018 0.935 1
0.5 0.299 0.014 0.970 1 0.301 0.018 0.955 1 0.301 0.013 0.960 1
0.1 0.300 0.012 0.980 1 0.303 0.018 0.960 1 0.298 0.012 0.950 1
0.1 1 0.283 0.066 0.960 0.975 0.285 0.106 0.945 0.765 0.307 0.086 0.945 0.965
0.5 0.300 0.057 0.965 0.995 0.307 0.085 0.965 0.925 0.304 0.066 0.975 0.995
0.1 0.301 0.061 0.965 1 0.303 0.085 0.965 0.950 0.300 0.059 0.960 1
40% 0.5 1 0.300 0.025 0.910 1 0.298 0.033 0.910 1 0.301 0.021 0.930 1
0.5 0.301 0.017 0.930 1 0.300 0.023 0.945 1 0.298 0.015 0.935 1
0.1 0.300 0.013 0.965 1 0.300 0.019 0.945 1 0.300 0.014 0.945 1
0.1 1 0.270 0.085 0.935 0.900 0.277 0.143 0.970 0.570 0.301 0.111 0.920 0.820
0.5 0.292 0.073 0.945 0.990 0.296 0.112 0.935 0.740 0.298 0.085 0.935 0.945
0.1 0.301 0.063 0.980 0.995 0.296 0.097 0.975 0.840 0.301 0.067 0.970 0.995
20% 0.5 1 0.306 0.028 0.855 1 0.297 0.040 0.860 1 0.301 0.025 0.910 1
0.5 0.301 0.018 0.955 1 0.301 0.029 0.930 1 0.299 0.021 0.925 1
0.1 0.302 0.015 0.960 1 0.300 0.021 0.940 1 0.299 0.016 0.915 1
0.1 1 0.281 0.097 0.930 0.820 0.273 0.147 0.950 0.490 0.286 0.124 0.925 0.740
0.5 0.283 0.092 0.935 0.860 0.291 0.127 0.970 0.630 0.292 0.097 0.920 0.885
0.1 0.316 0.073 0.950 0.990 0.308 0.099 0.985 0.820 0.308 0.071 0.970 0.990
0% 0.5 1 0.303 0.028 0.880 1 0.295 0.037 0.910 1 0.302 0.028 0.865 1
0.5 0.304 0.021 0.925 1 0.302 0.030 0.910 1 0.300 0.020 0.940 1
0.1 0.302 0.015 0.970 1 0.301 0.025 0.920 1 0.300 0.015 0.960 1
0.1 1 0.323 0.135 0.925 0.735 0.289 0.188 0.910 0.430 0.309 0.140 0.900 0.735
0.5 0.319 0.110 0.895 0.905 0.303 0.153 0.905 0.620 0.308 0.110 0.895 0.850
0.1 0.307 0.081 0.945 0.970 0.286 0.108 0.930 0.750 0.307 0.082 0.940 0.945
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Table 2 Causal effects estimated from simulated data when β = (β1, β2, β3) = 0. Mean, standard
deviation (sd) and coverage are displayed for the estimated causal effects of the exposures X1, X2
and X3 on the outcome Y , denoted as βˆ1, βˆ2 and βˆ3 respectively. There are 36 configurations
containing six sample overlapping rates (100%, 80%, 60%, 40%, 20%, 0%), two levels of IV strengths
(α = (α1, α2, α3) = 0.5 and 0.1) and three levels of effects of the confounder U on the exposures
(δ = (δ1, δ2, δ3) = 1,0.5 and 0.1). The effect of U on Y (δ4) is set to 1.
overlapping rate α δ
βˆ1 βˆ2 βˆ3
mean sd coverage mean sd coverage mean sd coverage
100% 0.5 1 0.000 0.001 0.980 0.000 0.002 0.985 0.000 0.001 0.990
0.5 0.000 0.003 0.980 0.001 0.005 0.955 0.000 0.003 0.990
0.1 0.001 0.006 0.965 0.001 0.010 0.940 0.001 0.006 0.990
0.1 1 0.002 0.006 0.975 0.003 0.010 0.980 0.000 0.006 0.975
0.5 0.007 0.009 0.935 0.011 0.015 0.930 -0.001 0.009 0.990
0.1 0.019 0.029 0.950 0.024 0.050 0.945 0.000 0.029 0.975
80% 0.5 1 0.005 0.012 0.965 0.005 0.011 0.975 0.001 0.006 0.990
0.5 0.003 0.010 0.980 0.004 0.011 0.975 0.000 0.007 0.965
0.1 0.001 0.009 0.975 0.002 0.016 0.965 0.000 0.010 0.975
0.1 1 0.028 0.026 0.950 0.027 0.042 0.960 0.002 0.033 0.990
0.5 0.029 0.030 0.935 0.032 0.049 0.950 0.002 0.036 0.975
0.1 0.024 0.049 0.965 0.025 0.077 0.960 0.001 0.049 0.995
60% 0.5 1 0.004 0.011 0.965 0.004 0.015 0.980 0.000 0.009 0.975
0.5 0.002 0.010 0.955 0.002 0.014 0.975 0.000 0.010 0.990
0.1 0.000 0.010 0.990 -0.001 0.017 0.965 0.001 0.012 0.970
0.1 1 0.034 0.037 0.915 0.032 0.057 0.965 -0.001 0.045 0.990
0.5 0.033 0.039 0.950 0.030 0.061 0.960 -0.001 0.049 0.965
0.1 0.010 0.061 0.945 0.009 0.089 0.935 0.002 0.059 0.945
40% 0.5 1 0.001 0.014 0.960 0.003 0.017 0.965 0.000 0.011 0.980
0.5 0.002 0.011 0.970 0.002 0.017 0.965 0.000 0.012 0.945
0.1 0.001 0.013 0.985 0.000 0.019 0.950 0.000 0.012 0.960
0.1 1 0.013 0.045 0.960 0.019 0.077 0.955 -0.001 0.060 0.955
0.5 0.013 0.051 0.975 0.013 0.078 0.965 -0.001 0.059 0.960
0.1 0.005 0.064 0.950 -0.002 0.082 0.980 0.000 0.061 0.970
20% 0.5 1 0.002 0.014 0.945 0.004 0.019 0.950 -0.001 0.012 0.985
0.5 -0.001 0.015 0.915 0.001 0.020 0.965 0.001 0.015 0.945
0.1 0.000 0.014 0.975 0.001 0.019 0.965 -0.001 0.014 0.955
0.1 1 0.012 0.057 0.955 -0.002 0.083 0.960 0.002 0.064 0.960
0.5 0.010 0.061 0.975 0.007 0.091 0.965 0.000 0.068 0.960
0.1 0.013 0.069 0.950 0.005 0.092 0.980 0.007 0.066 0.975
0% 0.5 1 0.003 0.014 0.960 0.001 0.020 0.945 0.000 0.014 0.960
0.5 0.002 0.013 0.970 0.001 0.023 0.930 0.000 0.014 0.955
0.1 0.001 0.015 0.960 0.000 0.022 0.940 0.001 0.014 0.945
0.1 1 0.011 0.080 0.920 -0.008 0.109 0.925 0.008 0.075 0.955
0.5 0.009 0.073 0.945 -0.005 0.102 0.940 0.005 0.071 0.980
0.1 0.010 0.072 0.955 -0.003 0.105 0.965 0.000 0.077 0.960
